Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 11/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NQO2 | P16083 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941162 | 0.84 | MAPT (0.66) | SLC9A1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL4943703 | 0.81 | SLC9A1 (0.75) | SLC9A1 | |
| SCHEMBL11781836 | 0.80 | MAPT (0.57) | MAPTNPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL4944134 | 0.80 | SLC9A1 (1.00) | SLC9A1 | |
| SCHEMBL27412638 | 0.80 | MAPT (0.53) | MAPTNPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL1317292 | 0.79 | KMT2A (0.66) | MAPTNPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL4943707 | 0.79 | SLC9A1 (1.00) | SLC9A1 | |
| Hydrochloric Acid SCHEMBL11779824 | 0.79 | MAPT (0.56) | MAPTNPC1RAB9AALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL3452251 | 0.78 | KMT2A (0.64) | MAPTNPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL3327876 | 0.78 | MAPT (0.60) | MAPTNPC1RAB9AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351843-B2 | Furancarbonylguanidine derivatives, their preparation and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-04-01 | — | — | US | disclosed |
| US-20070299131-A1 | Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299131-A1 | Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them | SLC9A1, NHERF1, SLC5A1 | SLC9A1 1/4885MAPT 4846/4885NPC1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.